Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats

European Journal of Pharmaceutical Sciences

Volumn 20, Issue 4-5, 2003, Pages 439-449

  Zhou, Qingyu ^a   Chan, Eli ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug interactions; Omeprazole; Pharmacodynamics; Pharmacokinetics; Rats; Warfarin

Indexed keywords

BLOOD; COAGULATION; HYDROXYLATION; METABOLITES; PHARMACOKINETICS; PROTEINS;

ANTICOAGULATION;

DRUG PRODUCTS;

OMEPRAZOLE; WARFARIN;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOMER; KIDNEY CLEARANCE; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; REDUCTION; THROMBOGENESIS;

EID: 0344514696     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.09.007     Document Type: Article

References (45)

1. Abernethy D.R., Kaminsky L.S., Dickinson T.H. Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther. 257:1991;411-415.
2. Andersson T. Omeprazole drug interaction studies. Clin. Pharmacokinet. 21:1991;195-212.
3. Andersson T., Regardh C.G., Dahl-Puustinen M.L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12:1990;415-416.
4. Banfield C., Rowland M. Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J. Pharm. Sci. 73:1984;1392-1396.
5. Breckenridge A., Orme M., Wesseling H., Lewis R.J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15:1974;424-430.
6. Chan E., McLachlan A., O'Reilly R., Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin. Pharmacol. Ther. 56:1994;286-294.
7. Choonara I.A., Malia R.G., Haynes B.P., Hay C.R., Cholerton S., Breckenridge A.M., Preston F.E., Park B.K. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br. J. Clin. Pharmacol. 25:1988;1-7.
8. Clissold S.P., Campoli-Richards D.M. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 32:1986;15-47.
9. Fasco M.J., Piper L.J., Kaminsky L.S. Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites. J. Chromatogr. 131:1977;365-373.
10. +)ATPase. Nature. 290:1981;159-161.
11. Guengerich F.P., Dannan G.A., Wright S.T., Martin M.V., Kaminsky L.S. Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry. 21:1982;6019-6030.
12. Harder S., Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin. Pharmacokinet. 30:1996;416-444.
13. Hermans J.J., Thijssen H.H. The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem. Pharmacol. 38:1989;3365-3370.
14. Hermans J.J., Thijssen H.H. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br. J. Pharmacol. 110:1993;482-490.
15. Hermodson M.A., Barker W.M., Link K.P. Studies on the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J. Med. Chem. 14:1971;167-169.
16. Hewick D.S., McEwen J. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J. Pharm. Pharmacol. 25:1973;458-465.
17. Hirsh J., Dalen J.E., Anderson D.R., Poller L., Bussey H., Ansell J., Deykin D., Brandt J.T. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 114:1998;445S-469S.
18. Howden C.W. Clinical pharmacology of omeprazole. Clin. Pharmacokinet. 20:1991;38-49.
19. Lewis R.J., Trager W.F., Chan K.K., Breckenridge A., Orme M., Rowland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. Clin. Invest. 53:1974;1607-1617.
20. Nedelcheva V., Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 24:1994;1151-1175.
21. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
22. Ohashi K., Sakamoto K., Sudo T., Tateishi T., Fujimura A., Shiga T., Ebihara A. Effects of diltiazem and cimetidine on theophylline oxidative metabolism. J. Clin. Pharmacol. 33:1993;1233-1237.
23. O'Reilly R.A., Goulart D.A., Kunze K.L., Neal J., Gibaldi M., Eddy A.C., Trager W.F. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. 51:1992;656-667.
24. Pohl L.R., Bales R., Trager W.F. Warfarin: stereochemical aspects of its metabolism in vivo in the rat. Res. Commun. Chem. Pathol. Pharmacol. 15:1976;233-256.
25. Porter, R.S., Sawyer, W.T., Lowenthal, D.T., 1986. Warfarin, in: Evans, W.E., Schentag, J.J., Jusko, W.J., Harrison, H. (Eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics Inc., Spokane, pp. 1057-1104.
26. Powell J.R., Donn K.H. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications. J. Clin. Gastroenterol. 5(Suppl. 1):1983;95-113.
27. Regårdh C.G., Gabrielsson M., Hoffman K.J., Löfberg I., Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand. J. Gastroenterol. Suppl. 108:1985;79-94.
28. Renberg L., Simonsson R., Hoffmann K.J. Identification of two main urinary metabolites of [14C]omeprazole in humans. Drug Metab. Dispos. 17:1989;69-76.
29. Rettie A.E., Eddy A.C., Heimark L.D., Gibaldi M., Trager W.F. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17:1989;265-270.
30. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., Trager W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5:1992;54-59.
31. Segel, I.H., 1975. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme system. Wiley, New York, pp. 100-171.
32. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
33. Sutfin T., Balmer K., Boström H., Eriksson S., Höglund P., Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther. Drug Monit. 11:1989;176-184.
34. Tateishi T., Ohashi K., Fujimura A., Ebihara A. The influence of diltiazem versus cimetidine on propranolol metabolism. J. Clin. Pharmacol. 32:1992;1099-1104.
35. Trager W.F., Lewis R.J., Garland W.A. Mass spectral analysis in the identification of human metabolites of warfarin. J. Med. Chem. 13:1970;1196-1204.
36. Unge P., Svedberg L.E., Nordgren A., Blom H., Andersson T., Lagerström P.O., Idström J.P. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34:1992;509-512.
37. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121:1994;676-683.
38. West B.D., Preis S., Schroeder C.H., Link K.P. Studies on the 4-hydroxycoumarins. XVII. The resolution and absolute configuration of warfarin. J. Am. Chem. Soc. 83:1961;2676-2679.
39. Whitlon D.S., Sadowski J.A., Suttie J.W. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 17:1978;1371-1377.
40. Winship L.C., McKenney J.M., Wright J.T. Jr., Wood J.H., Goodman R.P. The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. Pharmacotherapy. 5:1985;16-19.
41. Yacobi A., Levy G. Pharmacokinetics of the warfarin enantiomers in rats. J. Pharmacokinet. Biopharm. 2:1974;239-255.
42. Yacobi A., Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J. Pharmacokinet. Biopharm. 5:1977;123-131.
43. 10. J. Pharmacol. Toxicol. Methods. 40:1998;191-199.
44. Zhou S., Chan E. Effect of ubidecarenone on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. Drug Metabol. Drug Interact. 18:2001;99-122.
45. Zomorodi K., Houston J.B. Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharm. Res. 12:1995;1642-1646.